Apr 14, 2022

Genentech launches trial to study treatment for DME in underrepresented patients

by: Lynda Charters

According to the company, the trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations.

The Elevatum trial of faricimab-svoa (Vabysmo, Genentech Inc.), an anti-vascular endothelial growth factor drug, has begun, according to company representatives.

According to the company, the study was designed specifically “to ease the barriers to clinical trial participation faced by underrepresented racial and ethnic groups. That includes broadening eligibility criteria which could inadvertently exclude patients from various racial groups, ensuring diverse clinical site leaders, and providing transportation and other resources and services to make trial participation easier for people. The overall goal of the study is to better understand how these traditionally underrepresented patient populations with DME respond to treatment in order to help deliver better, more equitable care.”

Genentech said in a news release that it believes this is the first company-sponsored trial to focus on these patient populations.

Manuel Amador, MD, a lead investigator in the trial and medical director for Genentech, commented, that these groups “are disproportionately affected by diabetes and are at higher risk of developing vision-threatening DME.”……

Read more: https://www.ophthalmologytimes.com/view/genentech-launches-trial-to-study-treatment-for-dme-in-underrepresented-patients?utm_source=sfmc&utm_medium=email&utm_campaign=04142022_OT_HEI-22-OPD0444_OME-22-OPD0453_REG-22-OPL0116_ENL_Heidelberg_Omeros%20Cataract%20Therape%20-%20US&eKey=ZG9ubmFAbWFjdWxhcmhvcGUub3Jn

Source: Ophthalmology Times

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.